Results 141 to 150 of about 1,643 (175)

Antioxidant and longevity inducing properties of coconut water on human dermal fibroblasts. [PDF]

open access: yesHeliyon
Nakorn SN   +8 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

An allopurinol adherence tool using plasma oxypurinol concentrations

British Journal of Clinical Pharmacology, 2022
AbstractAimsThis study aimed to develop and evaluate an allopurinol adherence tool based on steady‐state oxypurinol plasma concentrations, allopurinol's active metabolite.MethodsPlasma oxypurinol concentrations were simulated stochastically from an oxypurinol pharmacokinetic model for allopurinol doses of 100‐800 mg daily, accounting for differences in
Natalia Smith‐Diaz   +6 more
openaire   +2 more sources

Oxypurinol Protects Normothermic Ischemic Hearts

Journal of Cardiac Surgery, 1990
Rabbit hearts were mounted on a Langendorff apparatus and after measurement of baseline hemodynamic function exposed to 30 minutes normothermic arrest. Hearts were reperfused at 37 degrees C with buffer solution containing oxypurinol in different concentration: group II (0.01 mM), group III (0.1 mM), group IV (1 mM). Group I did not receive active drug
J, Bergsland   +4 more
openaire   +2 more sources

Allopurinol and oxypurinol in human breast milk

The Clinical Investigator, 1993
To pregnant or breast feeding women drugs should be given with caution. We report the case of a 5-week-old breast-fed infant whose mother was taking 300mg allopurinol/day for 4 weeks. Allopurinol and oxypurinol were detected by HPLC in maternal plasma and breast milk with a method first described here.
I, Kamilli, U, Gresser
openaire   +2 more sources

Urinary-Tract Stones Resulting from the Excretion of Oxypurinol

New England Journal of Medicine, 1975
COMPOUNDS that inhibit the enzyme, xanthine oxidase, are useful in the treatment of disorders of purine metabolism.
A R, Landgrebe, W L, Nyhan, M, Coleman
openaire   +2 more sources

Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol

Clinical Pharmacokinetics, 2007
Allopurinol is the drug most widely used to lower the blood concentrations of urate and, therefore, to decrease the number of repeated attacks of gout. Allopurinol is rapidly and extensively metabolised to oxypurinol (oxipurinol), and the hypouricaemic efficacy of allopurinol is due very largely to this metabolite.
Richard O, Day   +5 more
openaire   +2 more sources

Oxypurinol reduces focal ischemic brain injury in the rat

Neuroscience Letters, 1991
When measured within 2 days of a unilateral occlusion of the middle cerebral artery (MCA) combined with tandem occlusion of the ipsilateral common carotid artery in rats, contralateral neurological deficits were detectable, with brain swelling and a consistent degree of neocortical infarction in the ipsilateral hemisphere.
Y, Lin, J W, Phillis
openaire   +2 more sources

Allergic Reaction to Allopurinol with Cross-Reactivity to Oxypurinol

Annals of Internal Medicine, 1976
A 25-year-old white man with gout and nephropathy and with a previous reaction to allopurinol was given a trial dose of oxypurinol. He developed malaise, a generalized erythematous reaction with edema, pruritus, and emesis; this was clinically identical to the reaction he experienced with allopurinol.
O, Lockard   +3 more
openaire   +2 more sources

Oxypurinol Nephrolithiasis in Regional Enteritis Secondary to Allopurinol Therapy

Annals of Internal Medicine, 1980
A patient with regional enteritis and recurrent uric acid nephrolithiasis was treated with allopurinol. While on 600 mg of allopurinol daily, she began to pass many small, soft, yellow stones. Analysis of the stones by liquid chromatographic and gas chromatograph/mass spectrometric techniques revealed that their major constituent was oxypurinol, a ...
R M, Stote   +5 more
openaire   +2 more sources

Effect of furosemide on renal excretion of oxypurinol and purine bases

Metabolism, 2001
To examine whether furosemide affects the plasma concentration and urinary excretion of purine bases and oxypurinol, we administered allopurinol (300 mg) orally to 6 healthy subjects and then administered furosemide (20 mg) intravenously 10 hours later. Furosemide (20 mg) decreased the urinary excretion of uric acid by 40% (P < .01), oxypurinol by 39% (
T, Yamamoto   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy